Description

Compound 4h is a novel selective MARK4 inhibitor with binding verified by molecular docking and flourescence biding assays.  MARK4 is a therapeutic target for cancer drug development due to its involvement in microtubule dynamics, cell cycle regulation and cancer progression.  Compound 4h exhibited apoptotic, antiproliferative and antioxidant activity in cell-based assays.  4h has a K value of 3.6 x 103 M-1 for human serum albumin demonstrating its remarkable transportation and delivery properties to the target site through the blood.  

Systematic Name:  (Z)-(5-nitro-1H-imidazol-1-yl)(2-(trifluoromethyl)phenyl)methanone oxime

SMILES:  FC(C1=C(C(N2C=NC=C2[N+]([O-])=O)=NO)C=CC=C1)(F)F

Formula:   C11H7F3N4O3

Mol Wt:  300.20

References

Peerzada MN et al. Design and Development of Small-Molecule Arylaldoxime/5-Nitroimidazole Hybrids as Potent Inhibitors of MARK4: A Promising Approach for Target-Based Cancer Therapy. ACS Omega. 2020 Sep 1;5(36):22759-22771.

Uploaded Files

There are no uploaded files